Smith & Nephew plc vs Sprott Uranium Miners ETF — how do they compare? Smith & Nephew plc trades at $30.05 (market cap $12.54B), while Sprott Uranium Miners ETF trades at $55.4. The key difference: Smith & Nephew plc pays a 2.65% dividend while Sprott Uranium Miners ETF pays none, and Sprott Uranium Miners ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | URNM | |
|---|---|---|
Market Cap | $12.54B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $38.70 | $83.99 |
52-Week Low | $28.73 | $44.14 |
Enterprise Value | $15.57B | — |
Dividend Yield | 2.65% | — |
Signals from Pluang's Aura AI — not financial advice
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
URNM trades at $55.39, up 1.45% today, with a bullish technical signal supported by moving averages. Recent news highlights nuclear energy's role in meeting AI power demand, with government funding and international deals creating positive momentum. The ETF focuses on uranium miners, offering concentrated exposure to the nuclear supply chain.
The outlook for URNM is positive due to growing nuclear energy demand from AI data centers and government support, though risks include uranium price volatility and concentrated miner exposure. Wall Street sentiment is mixed, with some analysts favoring pure-miner funds while others caution on valuation gaps versus spot prices.
Trailing returns across standard periods
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →